Access cutting-edge ovarian cancer treatment through this clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.
Access ovarian cancer specialists in Indianapolis at no cost
This study follows strict safety protocols and ethical guidelines
All study-related ovarian cancer treatment provided free
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
Sponsor: Daiichi Sankyo
Check if you qualify for this ovarian cancer clinical trial in Indianapolis, IN
If you're searching for ovarian cancer treatment options in Indianapolis, IN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Indianapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ovarian cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.